Conexiant
Login
  • The Analytical Scientist
  • The Cannabis Scientist
  • The Medicine Maker
  • The Ophthalmologist
  • The Pathologist
  • The Traditional Scientist
The Medicine Maker
  • Explore

    Explore

    • Latest
    • Features
    • Interviews
    • Business & Trends
    • Technology & Manufacturing
    • Product Profiles
    • White Papers

    Featured Topics

    • Biopharma
    • Small Molecules
    • Cell & Gene
    • Future of Pharma

    Issues

    • Latest Issue
    • Archive
    • Cell and Gene Therapy Supplement
  • Topics

    Topics

    • Cell & Gene
    • Bioprocessing
    • Drug Delivery
    • Drug Discovery
    • Development & Clinical
    • Formulation
    • Facilities & Equipment
    • Outsourcing
    • Packaging
    • Regulation & Standards
    • Small Molecules
    • Supply Chain
  • News & Blogs

    News & Blogs

    • Industry News
    • Research News
    • Blogs
  • Events
    • Live Events
    • Webinars
  • Community & Awards

    Community & Awards

    • Power List
    • Sitting Down With
    • Innovation Awards
    • Company of the Year Awards
    • Authors & Contributors
  • Multimedia
    • Video
    • eBooks
Subscribe
Subscribe
The Medicine Maker / Power List / 2025 / Advanced Medicine / Miguel Forte

Miguel Forte

President, ISCT and CEO, Kiji Therapeutics

  • Profile

Meet Miguel Forte

A member of the European Advisory Board with the Alliance for Regenerative Medicine, as well as a professor at the Faculty of Pharmacy, University of Lisbon, Miguel has been leading and championing the cell and gene sector for decades in academic, regulatory, and industry CEO roles. Heading up Kiji Therapeutics and sitting on the board of many other biotechs, including Swarm Oncology, Stembond Technologies, and mC4Tx, Miguel, a Power List veteran since 2016, returns following a successful 2024 and promising pipeline with Kiji Therapeutics.

“As technology evolves and improves, adoption will grow. Likewise, as competition increases, we will see a reduction in the cost of cell and gene products. We will progress from the smaller, orphan indications to larger patient number indications, evolving the business model from low numbers and high cost to higher numbers and lower costs.”

Recommended

The Medicine Maker
Subscribe

About

  • About Us
  • Work at Conexiant Europe
  • Terms and Conditions
  • Privacy Policy
  • Advertise With Us
  • Contact Us

Copyright © 2025 Texere Publishing Limited (trading as Conexiant), with registered number 08113419 whose registered office is at Booths No. 1, Booths Park, Chelford Road, Knutsford, England, WA16 8GS.